COVID-19 Omicron BA.5 Subvariant Dose Finding Infection Study

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 8, 2024

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions
SARS-CoV-2 Infection
Interventions
BIOLOGICAL

Omicron BA.5 SARS-CoV-2 challenge virus

The SARS-CoV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with Covid-19. All manufacturing steps are carried out in accordance with GMP by BioMARC, operating out of Colorado State University.

Trial Locations (1)

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER